| Autor: |
Theodore S. Hong, John T. Mullen, Beow Y. Yeap, Christian Baglini, Benjamin Christopher, Christine A. Ulysse, Rebecca S. Heist, Christopher R. Morse, Michael Lanuti, Melin J. Khandekar, Heather A. Shahzade, Isobel J. Fetter, Emily Van Seventer, Ryan B. Corcoran, David P. Ryan, Lorraine C. Drapek, Eric Roeland, Aparna R. Parikh, Florence K. Keane, Jill N. Allen, Samuel J. Klempner, Mari Mino-Kenudson, Christine E. Eyler, Jeffrey W. Clark, Jennifer Y. Wo |
| Rok vydání: |
2023 |
| Popis: |
Purpose:We performed a NCI-sponsored, prospective study of neoadjuvant FOLFIRINOX followed by chemoradiation with carboplatin/paclitaxel followed by surgery in patients with locally advanced gastric or gastroesophageal cancer.Patients and Methods:The primary objective was to determine completion rate of neoadjuvant FOLFIRINOX × 8 followed by chemoradiation. Secondary endpoints were toxicity and pathologic complete response (pCR) rate. Exploratory analysis was performed of circulating tumor DNA (ctDNA) to treatment response.Results:From October 2017 to June 2018, 25 patients were enrolled. All patients started FOLFIRINOX, 92% completed all eight planned cycles, and 88% completed chemoradiation. Twenty (80%) patients underwent surgical resection, and 7 had a pCR (35% in resected cohort, 28% intention to treat). Tumor-specific mutations were identified in 21 (84%) patients, of whom 4 and 17 patients had undetectable and detectable ctDNA at baseline, respectively. Presence of detectable post-chemoradiation ctDNA (P = 0.004) and/or postoperative ctDNA (P = 0.045) were associated with disease recurrence.Conclusions:Here we show neoadjuvant FOLFIRINOX followed by chemoradiation for locally advanced gastroesophageal cancer is feasible and yields a high rate of pCR. ctDNA appears to be a promising predictor of postoperative recurrence.See related commentary by Catenacci, p. 6281 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
